Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
59.61
-1.48 (-2.42%)
Nov 12, 2024, 4:00 PM EST - Market closed
Halozyme Therapeutics Employees
Halozyme Therapeutics had 373 employees as of December 31, 2023. The number of employees decreased by 20 or -5.09% compared to the previous year.
Employees
373
Change (1Y)
-20
Growth (1Y)
-5.09%
Revenue / Employee
$2,539,826
Profits / Employee
$1,052,190
Market Cap
7.58B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | 132 | -149 | -53.02% |
Dec 31, 2018 | 281 | 26 | 10.20% |
Dec 31, 2017 | 255 | -4 | -1.54% |
Dec 31, 2016 | 259 | 43 | 19.91% |
Dec 31, 2015 | 216 | 63 | 41.18% |
Dec 31, 2014 | 153 | -17 | -10.00% |
Dec 31, 2013 | 170 | 18 | 11.84% |
Dec 31, 2012 | 152 | 17 | 12.59% |
Dec 31, 2011 | 135 | 33 | 32.35% |
Dec 31, 2010 | 102 | -38 | -27.14% |
Dec 31, 2009 | 140 | 10 | 7.69% |
Dec 31, 2008 | 130 | 38 | 41.30% |
Dec 31, 2007 | 92 | 52 | 130.00% |
Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Grifols | 23,737 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Jazz Pharmaceuticals | 2,800 |
Legend Biotech | 1,826 |
Repligen | 1,783 |
Glaukos | 907 |
HALO News
- 7 days ago - Halozyme: Looking For More Growth Following Record Q3 Earnings - Seeking Alpha
- 11 days ago - Halozyme Announces Record Earnings, Guidance - FXEmpire
- 12 days ago - Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS - PRNewsWire
- 20 days ago - HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE - PRNewsWire
- 20 days ago - Halozyme to Report Third Quarter 2024 Financial and Operating Results - PRNewsWire
- 5 weeks ago - Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside - GuruFocus
- 5 weeks ago - Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE® - PRNewsWire